Why the study?
Recent trials challenged the assumption that viability predicts functional recovery and improved survival after revascularization, highlighting the need to re-evaluate viability testing alongside contemporary revascularization and guideline-directed medical therapy.
Does myocardial viability testing improve survival and functional recovery in patients with ischemic cardiomyopathy undergoing revascularization?
Design
Review
Key result
Myocardial viability testing does not independently predict survival benefit from revascularization in ischemic cardiomyopathy, whereas scar quantification may offer greater prognostic utility.
Authors
Loading...
Viability testing may not guide revascularization in ischemic cardiomyopathy; challenges traditional assumptions and leaves open its role with modern therapies.
Does myocardial viability testing improve survival and functional recovery in patients with ischemic cardiomyopathy undergoing revascularization?
This review highlights that contemporary trial data challenges the traditional use of myocardial viability testing to guide revascularization, suggesting a shift towards scar quantification.
Li et al. (2026) conducted a review in ischemic cardiomyopathy. Myocardial viability testing was evaluated. Myocardial viability testing does not independently predict survival benefit from revascularization in ischemic cardiomyopathy, whereas scar quantification may offer greater prognostic utility.